Astegolimab

Phase 3

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

RHHBYPhase 3$316.4B

Astegolimab Phase 3 Est. Readout

Astegolimab• Chronic Obstructive Pulmonary Disease (COPD)2,000

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

1 competitor in Chronic Obstructive Pulmonary Disease (COPD)

NVSIndacaterol 150 μg capsules

Phase 3

View Full Landscape

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial

NCT05595642

Last updated: 1/7/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts